Main Sector of relevance\IRC classification 10. Other Industrial Manufacturing Technologies
10.14 CITABARIN – pharmaceutical substance and medical drug for acute and chronic leukemia treatment
Developers’ contact information
State Scientific Institution “The Institute of Bioorganic Chemistry of the National Academy of Sciences of Belarus”
5, bldg. 2, Kuprevich Str., 220141 Minsk
Summary
CITABARIN is one of the most important drugs of the first generation used for acute and chronic leukemia treatment for children and adults.
Description
The original technology of chemosynthesis of the substance is protected by patent for invention of the Republic of Belarus No. 1589.
Technology type
Technical advantages and economic benefits
CITABARIN is one of the most important drugs of the first generation used for acute and chronic leukemia treatment for children and adults. The original and extremely effective technology of producing the substance and drug products of CITABARIN makes it possible to manufacture drug products in the form of freeze-dried powder used for injection solutions of 0.1, 0.5 and 1.0 g. The drug is not produced on the territory of CIS countries. The developed technology allows reducing the drug price in comparison with foreign analogues.
Technology differentiation and uniqueness
The original high-technology synthesis scheme
Context in which technology was identified
International Specialized Exhibition “Chemistry. Oil and Gas” 2006, 2008; National exhibition of the Republic of Belarus in the Bolivarian Republic of Venezuela “Expo Feria “BELARUS-2007”
Technological keywords
Antileukemia drug
Development Stage
Intellectual property rights
Range of applications
—
Classifier Used at the EU Innovation Relay Centres
Preferable Regions
Practical experience
Introduction of the technology in production.
Environmental impact
None.
Type of collaboration sought
Terms and restrictions
Terms of the license contract
Available technical assistance